"El Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC) es una asociación civil sin fines de lucro, entidad de bien público y universitaria. Nació en 1958 a partir de la visión innovadora del Dr. Norberto Quirno y de un grupo de discípulos comprometidos, que quisieron mejorar la calidad de la asistencia médica que se brindaba entonces. Esa visión ha convertido a esta institución en líder y referente en el área de la salud. A lo largo de sus 60 años de existencia, ha desarrollado su misión de centro médico académico basándose en sus objetivos fundacionales: la docencia universitaria y la investigación para mejorar la asistencia médica."

During the past decade, CEMIC conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 17 clinical trials were completed, i.e. on average, 58.6% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 7 clinical trials were completed. i.e. 35% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CEMIC" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Janssen Research & Development, LLC" with 8 trials sponsored, "Pfizer" with 3 trials sponsored, "Amgen" with 2 trials sponsored and "Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CEMIC" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator and "Cancer International Research Group (CIRG)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "CEMIC" are "Breast Cancer" (3 trials), "Alzheimer Disease" (2 trials), "Multiple Sclerosis" (2 trials), "Non-small Cell Lung Cancer" (2 trials) and "Rheumatoid Arthritis" (2 trials). Many other conditions were trialed in "CEMIC" in a lesser frequency.

Most popular intervention types in "CEMIC" are "Drug" (37 trials), "Other" (8 trials), "Biological" (2 trials), "Device" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Atezolizumab" (4 trials), "Docetaxel" (3 trials), "Erdafitinib" (3 trials) and "Methylprednisolone" (3 trials). Other intervention names were less common.

The vast majority of trials in "CEMIC" are 42 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "CEMIC". undefined are not yet recruiting, 16 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in CEMIC, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in CEMIC, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".